ReviewCurrent allergy and asthma reports2024
Allergic Conjunctivitis Management: Update on Ophthalmic Solutions.
Review in Current allergy and asthma reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06800274 (A Randomized, Single-Blind Clinical Investigation to Compare the Efficacy and Safety of N-Acetyl-Aspartyl-Glutamate), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Single-Blind Clinical Investigation to Compare the Efficacy and Safety of N-Acetyl-Aspartyl-Glutamate (NAAGA) Versus Azelastine Eye Drops in Patients With Allergic Conjunctivitis Associated With Tear Film Dysfunction
Who cites it
27 citing papers in PubMed.
- Olopatadine Exerts Multifaceted Protective Effects in an Ovalbumin-Induced Allergic Eye Disease Mouse Model.Bioengineering (Basel, Switzerland) · 2026Article
- The Impact of a Smartphone Reminder Application on Artificial Tear Adherence in Dry Eye Disease.Journal of clinical medicine · 2026Article
- Clinical Effect of Bacterial Suspension in Patients with Moderate-to-Severe Allergic Conjunctivitis.Journal of clinical medicine · 2026Article
- Seasonal variations and environmental factors associated with allergic ocular surface disease: A prospective observational study of clinical presentation patterns in South Asian region.International ophthalmology · 2026Observational
- Efficacy and safety of pilocarpine as a secretagogue versus artificial tears in the management of dry eye disease.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Article
- A mouse model of allergic conjunctivitis with mucosal immune-related gene and circRNA dysregulation.Frontiers in immunology · 2026Article
- Ocular Allergy Within the Framework of the EAACI Nomenclature of Allergic Diseases and Hypersensitivity Reactions.Allergy, asthma & immunology research · 2026Review
- Traditional Chinese medicine-related interventions for allergic conjunctivitis and vernal keratoconjunctivitis: clinical evidence, mechanistic hypotheses, and ocular surface safety considerations.Frontiers in medicine · 2026Review
- Ocular surface characteristics and dry eye symptoms in primary biliary cholangitis patients complicated with seasonal allergic conjunctivitis.International journal of ophthalmology · 2026Article
- Retrospective analysis of clinical efficacy and safety of fluorometholone combined with azelastine eye drops for seasonal allergic conjunctivitis.Frontiers in medicine · 2026Article
- Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: similarities and differences.Cancer chemotherapy and pharmacology · 2025Review
- Atopic disease and astigmatism: a population-based study-correspondence.Eye (London, England) · 2025Article
- [Drug Excipients. Necessary, but not Harmless].Farmaceuticos comunitarios · 2025Review
- FOXP3 inhibits inflammatory activation of conjunctival epithelial cells in allergic conjunctivitis via the KAT5/PDCD4 axis.Functional & integrative genomics · 2025Article
- Clinical and Biological Evaluation of NAAGA Versus Azelastine Eye Drops in Patients with Allergic Conjunctivitis and Tear Film Dysfunction: A Randomized Controlled Trial.Ophthalmology and therapy · 2025Article
- Topical Innovation: A Report on Epinastine Eyelid Cream for Patients With Mild Atopic Keratoconjunctivitis.Cureus · 2025Article
- The distribution patterns and clinical significance of serum immunoglobulin E in children with chalazion in Hubei, China.Translational pediatrics · 2025Article
- Stability and Efficacy of Mucoadhesive Eye Drops Containing Olopatadine HCl: Physicochemical, Functional, and Preclinical In Vivo Assessment.Pharmaceutics · 2025Article
- Metabolic Biomarkers Mediate Allergic Conjunctivitis via Circulating Inflammatory Proteins: Evidence From a Mendelian Randomization Study.Translational vision science & technology · 2025Article
- Knowledge attitude and practice of patients with allergic conjunctivitis towards their disease.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe aim of this review, is to present an updated revision of topical management of SAC and PAC, based on the available scientific evidence and focused on the impact of ophthalmic solution formulations on eye surface. RECENT
findingsPhysicians treating ocular allergy should be aware of tear film and tear film disruption in SAC and PAC, and how eye drop composition and additives affect the physiology of the allergic eye. Seasonal and perennial allergic conjunctivitis (SAC and PAC) are the most frequent causes of ocular allergy (OA), and both conditions are underdiagnosed and undertreated. SAC and PAC are immunoglobulin E (IgE)-mediated hypersensitivity reactions. The additional tear film disruption caused by the release of inflammatory mediators increases and exacerbates the impact of signs and symptoms and may trigger damage of the ocular surface. Comorbidities are frequent, and dry eye disease in particular must be considered. Clinical guidelines for the management of SAC and PAC recommend topical therapy with antihistamines, mast cells stabilizers or dualaction agents as first-line treatment, but care should be taken, as many medications contain other compounds that may contribute to ocular surface damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.